We are pioneering an innovative cancer therapeutic vaccine designed to fight cancer through a unique and highly targeted approach. Our focus is on developing cutting-edge adenocarcinoma immunotherapy that specifically aims at adenocarcinomas, which account for approximately 40% of all cancers and over 60% of cancer-related deaths globally. With over 1.7 million new cases of adenocarcinoma each year, we see an urgent need for more effective and personalized treatment options. Our approach is focused on the development of a therapeutic cancer vaccine based on Labyrinthin, a novel cancer target that can be found on the surface of adenocarcinomas. Unlike traditional cancer treatments, our synthetic peptide vaccine works by recruiting the body’s immune cells to recognize and destroy cancer cells without affecting healthy tissues. By targeting a specific protein found only on tumor cells, we are enhancing the precision of treatment and minimizing harmful side effects. More...
LabyRx’s flagship product, LabVax, is a synthetic peptide vaccine derived from the unique Labyrinthin protein, making it one of the most advanced therapeutic cancer vaccine on the market today. The therapeutic vaccine is designed to train the immune system to specifically target and destroy adenocarcinomas — one of the most common and deadly forms of cancer. This cancer immunotherapy vaccine represents a breakthrough in the field of immunotherapy for cancer. Our therapeutic cancer vaccine is engineered to induce a robust immune response by stimulating the production of antibodies that recognize and attack cancer cells expressing Labyrinthin. As part of a combination therapy with GM-CSF (sargramostim), a cytokine that enhances white blood cell production, LabVax strengthens the body’s natural immune defenses. This combination therapy is designed to deliver a potent immune system cancer treatment, offering a more personalized approach compared to traditional cancer therapies. More...
The field of immunotherapy for cancer is rapidly evolving, and LabyRx is leading the charge with a therapeutic vaccine that harness the power of the body’s immune system to fight cancer. Unlike traditional treatments like chemotherapy or radiation, our immunotherapy vaccine is designed to activate the immune system to target and eliminate cancer cells specifically, while leaving healthy tissues unharmed. Through our novel synthetic peptide vaccine, LabVax, we are able to offer an alternative treatment option for patients suffering from adenocarcinoma, a cancer type that has historically been difficult to treat with standard therapies. Our approach is focused on creating a vaccine for cancer patients that is not only effective but also reduce the long-term risk of recurrence, offering hope for a longer, healthier life after treatment. The potential of LabVax is vast, as it can be adapted to treat various cancer types, making it a groundbreaking product in the world of cancer immunotherapy. More...
As a leader in immuno-oncology biotech, LabyRx is committed to pushing the boundaries of cancer treatment by developing new, innovative therapies. Our goal is to offer the latest cancer treatments that are not only effective but also tailored to each patient’s specific genetic profile. This personalized approach is at the heart of our mission to transform cancer care and improve patient outcomes. We believe that therapeutic cancer vaccine therapies, when combined with antibody-based cancer therapy, hold the key to unlocking a new era of cancer immunotherapy. Monoclonal antibody drug development is another area where LabyRx is making strides, offering a dual mechanism of action that can significantly enhance the effectiveness of treatment. Our research continues to explore the synergy between therapeutic vaccines and monoclonal antibody therapies to create a comprehensive treatment plan that tackles cancer from multiple angles. As part of our ongoing commitment to innovation, LabyRx is also focused on developing immune system cancer treatments that can be used alongside checkpoint inhibitors and other immune-modulating therapies. By combining these powerful tools, we are laying the groundwork for more effective, less toxic, and long-lasting cancer treatments. More...
Adenocarcinoma is one of the most challenging forms of cancer to treat due to its complex biology and the way it spreads throughout the body. For years, traditional therapies have had limited success Adenocarcinoma is one of the most challenging forms of cancer to treat due to its complex biology and the way it spreads throughout the body. For years, traditional therapies have had limited success in treating this type of cancer. However, with our cancer immunotherapy vaccine, LabVax, we believe we are on the cusp of a major breakthrough. Our synthetic peptide vaccine specifically targets Labyrinthin expressed on adenocarcinoma cells, providing a more targeted approach to cancer treatment. This breakthrough has the potential to not only improve survival rates but also reduce the likelihood of cancer recurrence, offering new hope for patients diagnosed with adenocarcinoma. As we continue to test and refine our treatments in clinical trials, we remain committed to improving the lives of patients around the world. More...
Bring novel therapies that harnesses the power of the body’s immune system to treat patients suffering from a wide range of adenocarcinomas with effective, safe, and cutting edge medicine.